Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 16Urethral Neoplasms 4Prostatic Neoplasms 4Testicular Neoplasms 3Testicular Germ Cell Tumor 2Teratoma 2Kidney Neoplasms 2Carcinoma, Renal Cell 2Urothelial Carcinoma of the Bladder 1Ureteral Neoplasms 1Seminoma 1Renal Pelvis and Ureter Urothelial Carcinoma 1Ovarian Neoplasms 1Ovarian Germ Cell Cancer 1Neoplasm Metastasis 1Muscle Invasive Bladder Urothelial Carcinoma 1Endodermal Sinus Tumor 1Carcinoma, Transitional Cell 1Carcinoma, Embryonal 1Bladder Adenocarcinoma 1

Interventions

durvalumab 1Vinblastine 1Methotrexate 1Gemcitabine 1Doxorubicin 1Cystectomy 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bladder Adenocarcinoma × Vinblastine × Genitourinary × Clear all
NCT03912818 2023-09-11

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Stanford University

Phase 2 Terminated
7 enrolled 9 charts
GenitourinarySarcoma

Bladder Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡